An Open, Single Center, Non-randomized, Single Arm Clinical Study of Evaluating the Efficacy of Selinexor in the Maintenance Treatment of PTCL

NCT05822050 ↗

Phase 2/3 Unknown 20 enrolled The First Hospital of Jilin University

Non-randomizedSingle-groupOpen-labelPrevention

Summary

To evaluate the efficacy and safety of Selinexor maintenance therapy in PTCL patients who achieved complete response from frontline treatment, and to analyze the relationship between gene mutation in PTCL and disease prognosis and clinical features by using Next-generation sequencing (NGS) detection.

Timeline

Start: 2023-06-01
Primary completion: 2024-12-31
Completion: 2025-06-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Selinexor	Other / unclassified	60 mg	Oral

Indications

No indication recorded.